The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer

Part of paid clinical trials in Gilbert, Arizona.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT05961709
Phase
PHASE2
Status
Active Not Recruiting

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

To learn if cemiplimab can help to control dMMR colon cancer.

Key Dates

Start date
May 20, 2024
Status verified
Apr 2026
Primary completion
Apr 30, 2027
Completion
Apr 30, 2028

Study Design

Enrollment
50 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Cemiplimab
    Participants will receive cemiplimab by vein over about 30 minutes on Day 1 of each 3-week study cycle, up to 8 cycles.

Primary Outcome Measure

Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: Through study completion; an average of 1 year ]

Locations (5)

FacilityCityStateZIPSite coordinators
Banner - MD Anderson CancerGilbertArizona85234-
Baptist - MD Anderson Cancer CenterJacksonvilleFlorida32207-
OchsnerNew OrleansLouisiana70121-
Cooper University Medical CenterCamdenNew Jersey08103-
M D Anderson Cancer CenterHoustonTexas77030-

Find similar trials in Gilbert, AZ

By condition
Colorectal cancer
By specialty
OncologyGI oncology
By research site
Banner - MD Anderson Cancer· Gilbert, AZBaptist - MD Anderson Cancer Center· Jacksonville, FLOchsner· New Orleans, LACooper University Medical Center· Camden, NJM D Anderson Cancer Center· Houston, TX

Related Studies